百克生物：鼻喷流感减毒活疫苗获批准

Core Viewpoint - The company has received the drug registration certificate for the nasal spray influenza live attenuated vaccine from the National Medical Products Administration, which is expected to enhance the promotion and use of its influenza vaccine products [1] Group 1: Product Development - The vaccine is suitable for individuals aged 3 to 17 years and is administered via the nasal route, creating an initial immune barrier against influenza virus invasion in the respiratory tract [1] - The vaccine formulation has been upgraded from a freeze-dried form to a liquid form, making it more convenient for use [1] Group 2: Market Impact - The approval of this vaccine is anticipated to optimize the company's product structure and strengthen its core competitiveness in the market [1] - There is uncertainty regarding the timeline for the vaccine's market launch and sales, which presents potential investment risks [1]